Liquid biopsy reveals ability to tailor treatment

Cholangiocarcinoma (CCA) is a cancer that arises from bile ducts/channels draining bile in the liver and often includes the gallbladder cancers. CCA is the second most common form of cancerous liver lesions. In 2017, Linda Kilcrease came to Pashtoon Kasi, MD, MS (then at Mayo Clinic), with metastatic cancer, but it was not amenable or […]

Iowa results part of NEJM publication

A recent issue of the New England Journal of Medicine features the results of a multi-site clinical trial in which Dr. Mo Milhem and the University of Iowa’s Holden Comprehensive Cancer Center participated. Sorafenib, a kinase inhibitor primarily used to treat renal, hepatic, and thyroid carcinomas, was used against a placebo in a double-blind, phase […]

Talking It Through

For 90 minutes every other week, about a dozen people share a small, comfortable space and talk about their cancer. They talk about how it felt to learn of their diagnosis, they talk about wrangling with insurance companies, they talk about the next round of treatment, they talk about their fear that remission may end. […]

Cancer Center Designated “High Performing Site”

Last year, the Holden Comprehensive Cancer Center (HCCC) at the University of Iowa received its third renewal of its designation as “Comprehensive,” a label that brings with it a great deal of support from the National Institutes of Health’s National Cancer Institute (NCI). This designation recognizes the breadth, leadership, depth, and rigor of the HCCC’s […]